摘要
目的探讨氨磺必利联合草酸艾司西酞普兰治疗抑郁症的有效性和安全性。方法采用随机数字表法将符合《国际疾病分类(第10版)》(ICD-10)抑郁症诊断标准的78例抑郁症患者分为草酸艾司西酞普兰组(对照组,n=40)和草酸艾司西酞普兰联合氨磺必利组(研究组,n=38),疗程8周。于治疗前和治疗后第2、4、6、8周末采用汉密尔顿抑郁量表17项版(HAMD-17)评定疗效,采用副反应量表(TESS)评定安全性和不良反应。结果治疗2周后,两组HAMD-17总评分比较差异有统计学意义(P<0.01)。治疗4周后,研究组HAMD-17焦虑躯体化因子评分、体重因子评分、阻滞因子评分及总评分均较对照组低(P<0.05或0.01)。两组总有效率差异有统计学意义(χ2=2.734,P<0.01)。研究组与对照组口干、恶心、呕吐及便秘的发生率差异有统计学意义(P<0.01)。结论在抑郁症的临床治疗过程中,相对于单用草酸艾司西酞普兰,联合用药可能会更有效地改善躯体症状,减轻早期消化道不良反应,加快起效时间。
Objective To compare the efficacy and safety of escitalopram oxalate monotherapy and escitalopram oxalatecombined with amisulpride in the treatment of major depression. Methods 78 patients with depression which met the depressioncriterion of ICD -1 0 were randomly divided into the study group （n =38） and the control group （n =40） with random number tablemethod. The study group were treated with escitalopram oxalate combined with amisulpride, and the control group were treated withescitalopram oxalate monotherapy. The curative effect was evaluated with Hamilton Depression Scale -17 item （HAMD - 17） before andafter 2nd, 4th, 6th, 8th weekend of treatment, and adverse reactions were assessed with Treatment Emergent Symptom Scale （TESS）.Results At the end of the 2nd week, there was significant difference in the HAMD - 17 scores between two groups（P 〈0. 01） , and after4 weeks of treatment, anxiety/somatization factor score, weight factor score, retardation factor score and total score of the HAMD -17 inthe study group were significantly lower than those in the control group （P 〈0. 05 or 0 .0 1 ）. And there was significant differencebetween the two groups in the total effective rate（^2 = 2. 734 ,P 〈 0. 01）. But there was no difference between the two groups in theincidence of adverse reactions（P 〉0. 05） , apart from dry mouth, nausea and vomiting and constipation（ P 〈0. 01） . Conclusion Thetreatment of escitalopram oxalate combined with amisulpride can effectively improve somatic symptoms and reduce early gastrointestinaladverse reactions than escitalopram oxalate monotherapy in the treatment of major depression. And therefore accelerate the onset time,increase the efficacy.
出处
《四川精神卫生》
2016年第2期143-145,共3页
Sichuan Mental Health
